Burzynski Research Institute (BZYR) Return on Capital Employed (2012 - 2021)
Burzynski Research Institute (BZYR) posted Return on Capital Employed of 2876.84% for Q1 2021, up 157.31% sequentially from 1118.05% in Q1 2020, and up 175879.0% YoY from N/an in Q1 2020.
Burzynski Research Institute (BZYR) Return on Capital Employed (2012 - 2021) Analysis & Trends
Burzynski Research Institute has reported Return on Capital Employed for 10 years, with the latest figure at 2876.84% in Q1 2021.
- Quarterly Return on Capital Employed rose 175879.0% year-over-year to 2876.84% in Q1 2021, while the trailing twelve-month figure through Feb 2021 was 2876.84% (up 175879.0% YoY) and the FY2021 annual result came in at 3576.83%, up 249712.0% from the prior year.
- Return on Capital Employed improved to 2876.84% in Q1 2021 per BZYR's latest filing, from 1118.05% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 3976.52% in Q1 2017 and troughed at 905.31% in Q1 2019.
- A 5-year average of 2085.2% and a median of 1549.26% in 2018 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2017 and 2018: Return on Capital Employed jumped 212796 bps in 2017, then sank 242727 bps in 2018.
- Over 5 years, Return on Capital Employed stood at 3976.52% in 2017, then tumbled by 61 bps to 1549.26% in 2018, then sank by 42 bps to 905.31% in 2019, then grew by 23 bps to 1118.05% in 2020, then soared by 157 bps to 2876.84% in 2021.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 2876.84%, 1118.05%, and 905.31% for Q1 2021, Q1 2020, and Q1 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2021 | 2,876.84% |
| Feb 29, 2020 | 1,118.05% |
| Feb 28, 2019 | 905.31% |
| Feb 28, 2018 | 1,549.26% |
| Feb 28, 2017 | 3,976.52% |
| Feb 29, 2016 | 1,848.56% |
| Feb 28, 2015 | 2,089.69% |
| Feb 28, 2014 | 2,459.80% |
| Feb 28, 2013 | 6,800.60% |
| Feb 29, 2012 | 16,646.63% |